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Introduction: Malignant pleural mesothelioma (MPM) is a lethal
tumor related to asbestos exposure. At present, the only instruments
for screening and diagnosis are based on radiological tests, posing
evident economic and radio-protectionist problems. Some authors
are evaluating biological indicators, such as plasma osteopontin
(pOPN) and serum soluble mesothelin-related peptides (SMRP).
This study aimed to evaluate whether a combination of these two
markers could increase sensitivity and specificity in diagnosis of
epithelioid MPM.
Methods: We enrolled 93 healthy subjects, 111 individuals with
benign respiratory disease (BRD), and 31 patients with MPM,
histologically and/or cytologically confirmed. SMRP and pOPN
levels were determined using commercially available enzyme-linked
immunosorbent assay kits. Though a logistic regression analysis,
SMRP and pOPN were combined and translated into a new index,
called “combined risk index.”
Results: Differences in both SMRP and pOPN mean values between
epithelial MPM patients and healthy subjects or BRD patients were
statistically significant (p  0.0001), whereas there was no differ-
ence in SMRP and pOPN mean values between healthy subjects and
BRD patients. The performance in MPM diagnosis resulted im-
proved by the combination of the two markers. The results of our
study should be confirmed by a larger scale and, possibly, a multi-
center study, which could better take into consideration the influence
of some possible confounding factors such as glomerular filtration
rate and other blood parameters.
Conclusions: We combined SMRP and pOPN dosages to increase
diagnostic accuracy. This study showed for the first time that
combined SMRP and pOPN measurements can increase both sen-
sitivity and specificity in terms of combined risk index.
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Malignant mesothelioma is a lethal tumor arising fromthe serosal covering pleura and, less frequently, the
pericardial and peritoneal cavities and from the tunica vagi-
nalis of the testis.
Its relationship to asbestos exposure has been estab-
lished, but several aspects of its etiopathological mechanism
are still under examination. Other factors such as viral agents
and/or genetic determinants may also play a role.1,2
Italy was an important producer and importer of raw
asbestos until it was banned in 1992, and our country is now
experiencing severe public health consequences. Until 2004,
the national standardized mortality rate in Italy was 3.42
(100,000 inhabitants) for men.3 National Standardized
Mortality Ratios (MR) are often quite different even within
countries with a similar history of asbestos use, which can be
explained by both a inhomogeneous development in national
surveillance systems and, partially, an intrinsic bias in ma-
lignant pleural mesothelioma (MPM) registering according to
the International Classification of Disease. In a recent study
of Nishikawa et al., the world global median age-adjusted
MR was as high as 7.8 deaths/million/yr, whereas in Europe
it ranged from 1.9 in Romania up to 30.0 in Netherlands and
31.1 in the United Kingdom. In general, MRs were higher in
Northern and Western than in the Eastern and Southern
European countries. High MRs were observed in Australia
(25.5), New Zealand (20.5), intermediate in Canada (10.3)
and USA (9.0), and low or very low in some Asian or Central
and Southern American countries. Remarkably, almost all
countries with low MRs showed an increasing trend in MPM
mortality.4 The incidence of mesothelioma is expected to
increase in many other countries such as Britain,5 Australia,6
and the United States,7 due to a widespread use of asbestos in
the past.
Latency time for MPM shows great variability, but a
latency period shorter than 10 years is very rare.
Early diagnosis and differential diagnosis are very dif-
ficult. Because of the usually advanced stage at presentation,
only a minority of patients are eligible for radical surgery8;
most are candidates for chemotherapy during the course of
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their disease. Retrospective studies report median survival of
less than 1 year and 5-year survival rates of 1% or less.9
Despite this dramatic scenario, at present, the only
instruments for screening and early diagnosis are based on
radiological tests, with evident economical problems as well
as radio-protectionist issues, due to cancer risk added by
the use of ionizing radiation-based diagnostic tests (i.e.,
chest radiography and computed tomography). For this
reason, some authors are evaluating biological indicators
as screening and early diagnosis markers, such as serum
and plasma osteopontin (OPN) and soluble mesothelin-
related peptides (SMRP).
OPN is a glycoprotein overexpressed in several human
neoplasms such as lung, breast, and colon cancer.10 OPN
modulates cell-matrix interactions; high levels correlate with
tumor invasion, progression, and metastasis. Serum OPN
(sOPN) levels in patients with MPM have been reported to be
higher than in healthy subjects.11,12 However, a recent study
by Park et al.13 reported that sOPN levels are elevated in
subjects with asbestos-related disorders without MPM; these
data indicate that sOPN may be influenced by nonmalignant
processes. In a relatively small population of workers previ-
ously exposed to asbestos, Foddis et al.14 observed that age,
duration of exposure, restrictive respiratory function, and
smoking habit could affect the result of sOPN measurement.
Recently, our study group investigated the usefulness
of plasma OPN (pOPN).15 Mean pOPN values were signifi-
cantly higher in MPM patients than in controls and BRD
patients, and no statistically significant difference was found
comparing the mean value of controls and BRD groups.
Moreover, neither clinical status nor smoking habit could
affect the result of the pOPN measurement.
Mesothelin is a 40 kDa cell surface glycophosphatidy-
linositol-anchored protein expressed at a low level by normal
mesothelial cells in the pleura, peritoneum, and pericardium.
It is highly expressed in pancreatic cancer, ovarian cancer,
mesotheliomas, and some other cancers.16,17 Mesothelin has
been proposed for diagnosis and prognosis of epithelioid
MPM as an immunohistochemical pleural fluid, and serum
marker.12,18–24
The clinical limitation of these studies is that serum
mesothelin is useful for diagnosis and possibly for monitoring
patients but has insufficient sensitivity.25 The aim of this
study was to evaluate whether a combination of the two
markers (serum mesothelin and pOPN) could increase sensi-
tivity and specificity in diagnosis of epithelioid MPM.
PATIENTS AND METHODS
Patients and Controls
This study was approved by the ethical committee for
pharmaceutical experimentation of Pisa Hospital. All subjects
gave written and oral informed consent.
Serum and plasma samples were available from con-
secutive patients presenting at the University Hospital of
Pisa. We studied 93 healthy subjects, 111 individuals with
benign respiratory disease, and 31 patients with MPM, his-
tologically and/or cytologically confirmed. All subjects un-
derwent clinical examination, including chest radiography,
functional respiratory tests, and in some cases low-dose
computerized tomography. According to these results, those
who were negative for all the tests were classified as “healthy
subjects.” Subjects designated as BRDs were patients suffer-
ing from one or more of the following diseases: lung
asbestosis, asbestos pleuritis, emphysema, lung fibrosis,
and pleural fluid. Of the BRDs, 13 had pleural plaques and
48 unspecific lung nodules (10 mm diameter) but no
functional impairment or clinical symptoms. Healthy and
BRD subjects were recruited within a population of work-
ers previously exposed to asbestos, undergoing a preven-
tive cancer program.
MPM patients were enrolled at the time of diagnosis,
before beginning any therapeutic treatment. All MPMs were
of epithelioid type, histologically confirmed. Mixed and sar-
chomatoid mesothelioma were excluded because of the pau-
city of available cases and the proved lack of association
between SMRP and nonepithelioid MPM.19
Biomarker Assays
The Human Osteopontin Assay Kit (IBL, Gunma, Ja-
pan), a commercially available ELISA (enzyme-linked im-
munosorbent assay), was used to determine the level of
pOPN. Briefly, plasma samples were diluted 1:10 with EIA
buffer and 100 l of blank, and standards and samples were
applied in duplicate in a O-17 antibody precoated microwell
plate and were incubated for 1 hour at 37°C. The plate was
washed eight times and 100 l of labeled antibody 10A16
was added in each well. After an incubation period of 30
minutes at 4°C, the plate was washed nine times and chro-
mogen was added. The plate was incubated for 30 minutes at
room temperature in the dark and Stop solution was added.
Adsorbance read at 450 nm was used to quantify the OPN
concentration in ng/ml by comparison with the standard curve
plotted by Microsoft Excel.
Serum mesothelin concentration was measured using a
sandwich-type ELISA, Mesomark (Cisbio International, Gif/
Yvette, France), according to instructions. Briefly, patient
serum samples were diluted 1:101 with the assay diluent.
Next, 100 l of blank, provided standards, and samples were
applied in duplicate in a microwell plate precoated with
antibody 4H3. After 1-hour incubation on a shaking plate at
room temperature, the wells were washed and antibody
OV569-HRP was added for 1 hour. After a second washing
step, TMB substrate was added to wells for 15 minutes, and
then 100 l of stop solution was added. Absorbance read at
450 nm was used to quantify the SMRP concentration in nM
by comparison of mean of the duplicate measurement with a
calibration curve fitted by CourbesRD software (InstallShield
Corporation, Inc., France).
Statistics
All data were presented as mean  SD. Comparisons
between groups were performed using the Mann-Whitney U
test for unpaired samples. Linear regression analysis was
used to determine the correlation between SMRP and pOPN
levels. Logistic regression was used to determine the weight
given to each marker and then to calculate a specific formula
to provide a combined risk index. To estimate whether this
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marker combination might increase the markers performance
in MPM detection, receiver operating characteristic (ROC)
curves were plotted, and the areas under curves (AUC) were
calculated with their 95% confidence intervals (95% CI)
using standard techniques to evaluate sensitivity and speci-
ficity of each marker and their combination. Statistical anal-
yses were performed with SPSS (Statistical Package for the
Social Sciences).26
RESULTS
We measured SMRP and pOPN levels in all subjects.
Characteristics of study subjects regarding age, gender, as-
bestos exposure, and MPM stage according to IMIG (Inter-
national Mesothelioma Interest Group) classification are sum-
marized in Table 1. Mean pOPN levels for MPM patients,
healthy subjects, and BRD patients were 1322.56  998.98,
553.10  387.67, and 533.77  394.63 ng/ml, respectively
(Figure 1A). The difference in pOPN mean values between
epithelioid MPM patients and healthy subjects or BRD pa-
tients was statistically significant (p  0.0001). Serum me-
sothelin levels differed among epithelial MPM patients
(2.52  4.10 nM) and healthy subjects (0.71  0.45 nM) or
patients with BRD (0.82  0.51 nM), as shown in Figure 1B.
Mean values of both SMRP and pOPN did not differ in the
two groups of healthy subjects and BRD patients, as shown in
Figure 1.
To assess the clinical potential of the two markers, we
compared sensitivities and specificities of SMRP with those
of pOPN. The areas under the ROC curves (AUC) were
calculated for SMRP and pOPN one at a time, showing that
each marker alone can highly discriminate epithelial MPM
patients from healthy subjects and BRD patients. The dis-
criminative power of each marker may be potentially in-
creased using a logistic regression analysis, which can predict
the probability of occurrence of an event, such as a tumor as
MPM. Probability of the risk of developing epithelial MPM
FIGURE 1. Plasma osteopontin (OPN) (A) and soluble mesothelin-related peptides (SMRP) (B) levels in healthy subjects, epi-
thelial MPM patients, and BRD patients. MPM, malignant pleural mesothelioma; BRD, benign respiratory disease.
FIGURE 2. Receiver operating characteristic curves in case
of predicted probability for pOPN, SMRP, and combination
of pOPN and SMRP. The areas under the curves (AUCs)
were determined for each marker, comparing healthy sub-
jects and MPM patients. pOPN, plasma osteopontin; SMRP,
soluble mesothelin-related peptides; MPM, malignant pleural
mesothelioma.
TABLE 1. Characteristic of Study Subjects
Age
Gender
(M/F)
Asbestos
Exposure Stage
Healthy subjects
(n  93)
57.2  7.2 92/1 93 (100%) —
BRD (n  111) 60.1  8.7 108/3 111 (100%) —
MPM (n  31) 67.4  7.9 24/7 20 (64.5%) II (n  19)
III (n  12)
BRD, benign respiratory disease; MPM, malignant pleural mesothelioma.
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was calculated using the logistic function “p  exp (4.648
 0.002X1  0.975X2)/(1  exp (4.65  0.002X1 
0.975X2)),” where X1 pOPN level and X2 SMPR level.
According to this formula, the AUC increases from 0.795 
0.05 for pOPN and 0.762 0.05 for SMRP to 0.873 0.043
for the combination of SMRP and pOPN (Figure 2). Then, the
combination of these two markers had a better performance in
MPM diagnosis compared with each single marker, as shown
in Table 2.
Pearson’s correlation was significant (coefficient 
0.194, p  0.005), plotting concentrations of SMRP and
pOPN in the same figure (Figure 3A) for healthy subjects and
BRD patients (n  204). Using the best cutsoff obtained by
ROC curve analysis for each individual marker (1 nM for
SMRP and 885 mg/ml for pOPN), the 67.7% of subjects were
below the cutoff values for both markers, as expected. Linear
regression analysis results proved a correlation between
SMRP and pOPN levels only in healthy controls and BRD
(Figure 3C) but not in MPM patients (Figure 3B) or in all
study subjects (Figure 3D).
DISCUSSION
The remarkable novelty of this study is the demonstra-
tion that the combination of two markers, through the appli-
cation of a logistic regression formula, is able to increase both
sensitivity and specificity in MPM diagnosis. Traditionally,
the application of a multitest screening is performed in two
alternative manners. The biologic sample is analyzed simul-
taneously with all the tests and considered positive even if
only one of the test resulted positive (parallel assessment).
Otherwise, to be considered positive, a biologic sample must
be positive at the first test and also at one or more of the
subsequent tests (serial assessment). The first approach im-
prove the sensitivity but negatively affect the specificity,
whereas the second approach gives opposite performance,
worsening the sensitivity in favor of a better specificity. To
circumvent this limitation, we tried the application of a
mathematical combination of the two most reliable markers
ever tested before with MPM. Surprisingly, we obtained a
simultaneous increase of both sensitivity and specificity as
described in Table 2. Although statistical analysis provided
us with cutoffs, which are values associated with the best
combination of sensitivity and specificity, the choice of the
cutoff should be considered according to the sanitary context
where the markers are used. In particular, in the case of
cancer screening programs for healthy workers previously
exposed to asbestos, where MPM incidence rate is still low,
even higher than in the general population, and biomarkers
are only a part of protocol to be interpreted together with the
results of other preventive exams (clinical and radiologic
examinations, functional respiratory tests, etc.), it should be
suggested to adopt more specific even less sensitive cutoff.
The findings of this study allow to choose highly
specific cutoffs with a relatively decrease of sensitivity, and
consequently, less false negatives in both preventive and
clinical applications. MPM diagnosis, even when symptoms
are present, is still a difficult issue.
MPM does not show specific symptoms that allow its
identification during early stages. Diagnosis is frequently
made only after progression to later stages, at which point the
tumor’s dissemination limits effective treatment. Therefore,
developing sensitive and specific methods for early detection
has been a priority. Serum markers have been suggested as
useful tools for the diagnosis and follow-up of patients with
MPM by different authors. To date, one of the most promis-
ing biological markers in diagnosis, prognosis, and clinical
monitoring for MPM has been serum mesothelin, also called
SMRP. However, usefulness of SMRP is limited due to its
inadequate sensitivity. For example, in our experience, only
64% of MPM patients have SMRP above the best cutoff.22
In other kinds of tumors, combining markers often
improves the performance of diagnosis and screening strate-
TABLE 2. Comparison between Sensitivities and Specificities of SMRP, pOPN and Combination of the Markers
A
SMRP
Sensitivity % 80 85 90 95 61.3 51.6 51.6 45.2
Specificity % 50.5 45.1 40.7 36.8 80 85 90 95
Cut-off nM .675 .605 .575 .555 1.01 1.14 1.32 1.56
B
pOPN
Sensitivity % 80 85 90 95 71.0 67.7 58.1 29.5
Specificity % 68.1 53.4 31.9 31.4 80 85 90 95
Cut-off ng/ml 577.1 428.2 336.9 334.5 782.1 902.7 1074.6 1423.9
C
Combining SMRP and pOPN
Sensitivity % 80 85 90 95 83.9 83.9 80.6 64.5
Specificity % 91.2 89.7 45.1 37.7 80 85 90 95
Cut-off combined
risk index
.165 .153 .044 .039 .106 .117 .156 .251
SMRP, soluble mesothelin-related peptides; pOPN, plasmatic osteopontin.
Cristaudo et al. Journal of Thoracic Oncology • Volume 6, Number 9, September 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1590
gies. However, to date, no combination has been able to
increase diagnostic accuracy in MPM, as reported by several
authors27–32 (Table 3).
Among these, Creaney et al.29 studied SMRP, MPF
(Megaryocyte potentiating factor), and sOPN levels in 66
MPM patients, 20 healthy individuals, 21 patients with lung
or pleural disease, 30 patients with benign pleural effusions,
and 30 patients with other malignancies. This study reported
that at high levels of specificity (95%), MPF had a sensitivity
of 34%, sOPN of 47%, and SMRP of 73%. Using logic
regression, the combination of these three markers did not
improve sensitivity for detecting mesothelioma over that of
SMRP alone.
Another marker used in diagnosing MPM is sOPN,
which although reported to be useful for detecting MPM in
asbestos-exposed subjects, may be influenced by nonmalig-
nant processes.11 Recently, our research group examined the
usefulness of osteopontin on plasma matrices in diagnosing
epithelial MPM, evaluating possible confounding factors and
the impact of clinical variables as well as lung function or
imaging parameters.15 Moreover, we analyzed the influence
of preanalytic variables on pOPN and sOPN, comparing the
performances of the marker in the two different matrices. In
that study, we showed that both pOPN and sOPN levels were
significantly higher in epithelial MPM than in the healthy
control and BRD groups. The application of a ROC curve for
pOPN resulted in an AUC value of 0.780, with a sensitivity
of 68.8% and a specificity of 84.5%. Regarding sOPN, the
AUC value was 0.725, with a sensitivity of 62.5% and a
specificity of 87.3%. In the control group, no significant
correlation was observed between age, duration of asbestos
exposure, pack-years in current smokers, lung function or
imaging parameters and pOPN or sOPN. Although both
markers showed similar performances, our results suggested
that pOPN is preferable because in pOPN is more stable and
therefore measurements are more reliable.
The improvement provided by this new statistical ap-
proach is clearly evident, comparing the different combina-
tion of sensitivity and specificity, among SMRP, pOPN, and
the combined risk index as shown in Table 2. In particular,
for the best cutoff of combined risk index (0.165), SMRP was
1.057 nM and pOPN was 995.04 ng/ml.
The application of this new equation using the combina-
tion of those markers in healthy surveillance programs could be
useful considering the significant decrease of both false-positive
and false-negative subjects. Such reduction is very important to
avoid both ethical and economic undesirable effects, to incorrect
“disease labeling” such as unnecessary increased concern, psy-
FIGURE 3. A, Plotted SMRP and pOPN concentrations in healthy subjects and BRD patients. The horizontal dotted line repre-
sents the best cutoff for pOPN (878.65 ng/ml) and the vertical dotted line for SMRP (1 nM). B, Linear regression between
SMRP and pOPN levels in MPM patients. C, Linear regression between SMRP and pOPN levels in healthy controls and BRD
patients. D, Linear regression between SMRP and pOPN levels in all study subjects. pOPN, plasma osteopontin; SMRP, soluble
mesothelin-related peptides; BRD, benign respiratory disease.
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chological disorders, or unreasonable increase of radiologic
exams within a healthy population.
Our data suggest that, although limited to the ephite-
lioid histotype, the combined use of these markers can be
useful in clinical applications. The results of our study should
be confirmed by a larger scale and, possibly, a multicenter
study, which could better take into consideration the influ-
ence of some possible confounding factors such as glomeru-
lar filtration rate and other blood parameters.
Finally, this study showed for the first time that a combi-
nation of SMRP and pOPN measurements can increase both
sensitivity and specificity in term of combined risk index.
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